Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06928233 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Association of TNFAIP3 With Immune-mediated TTP

Study acronym: A20iTTP
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 27, 2026 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Active, Not Recruiting to Recruiting
    • Start date: Apr 4, 2025 to Apr 7, 2025
    • Site details revised
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to investigate whether genetic variation in the TNFAIP3 locus is associated with immune-mediated thrombotic thrombocytopenic purpura (iTTP), and whether such association is mediated by decreased expression of A20 (TNFAIP3). The study includes a case-control design to assess genotype-expression association and a cohort study to evaluate clinical outcomes such as disease relapse.
Trial Details
NCT Number NCT06928233
Lead Sponsor Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Conditions
(from sponsor)		 Thrombotic Thrombocytopenic Purpura, Acquired
Related terms Thrombotic thrombocytopenic purpura, acquired
Enrollment 400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov